Malignant Hyperthermia News and Research

RSS

AICAR might protect against heat stress in MH-susceptible individuals

Malignant hyperthermia (MH) is a life-threatening genetic muscle disorder, most commonly triggered in those at risk by certain types of drugs used during anesthesia. Heat stroke, on the other hand, most commonly occurs in individuals in response to physical exertion in hot/humid environments. While their common triggers may differ, the signs associated with MH and heat stroke are remarkably similar - uncontrolled muscle contractions, dangerous increases in body temperature, and muscle breakdown leading to the release of toxins in the blood which may cause cardiac arrhythmias and death. Immediate treatment for these conditions is crucial.

13 Jan 2012

AICAR therapy may combat heat stroke

We've all seen the story in the news before. Whether it's the death of a physically fit high school athlete at football training camp in August, or of an elderly woman gardening in the middle of the day in July, heat stroke is a serious, life-threatening condition for which there is no treatment beyond submersion in ice water or the application of ice packs to cool the body to a normal temperature.

8 Jan 2012

ASCs need to develop policies for management of malignant hyperthermia

As the number of surgical procedures performed outside hospitals continues to increase, ambulatory surgical centers (ASCs) need to develop policies for managing malignant hyperthermia—a rare but serious reaction to anesthetics, according to an expert panel report in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

23 Dec 2011

HRM curve analysis identifies patients at risk of MH

A new DNA test may make it much simpler to identify patients at risk of malignant hyperthermia (MH)—a rare but life-threatening complication of exposure to common anesthetics reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

2 Nov 2011

Heat, extreme exercise or febrile illness may also trigger MH

Malignant hyperthermia (MH) is a potentially life-threatening inherited disorder of muscle. Patients who are at risk for MH usually have no outward signs of muscle problems. However, when exposed to certain commonly used general anesthetics they may develop very high body temperature, increased heart rate and muscle breakdown. If not recognized and treated promptly MH may be fatal.

1 Nov 2011

MHAUS sponsors one-day conference on Malignant Hyperthermia

Medical professionals, patients and families can learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia at a one-day Malignant Hyperthermia conference happening from 10 am to 4 pm June 25 at Lake Receptions located in Mt. Dora, Florida.

17 May 2011

US WorldMeds announces acquisition of Solstice Neurosciences for $35M

US WorldMeds, LLC, a Kentucky-based specialty pharmaceutical company that develops unique products to address unmet medical needs, today announced it has acquired Solstice Neurosciences, Inc. for $35 million. The acquisition expands US WorldMeds' operations, adds to the company's growing portfolio of products and enhances the company's ability to create and deliver high-quality specialty pharmaceutical products to its targeted global markets.

16 Aug 2010

US WorldMeds launches Revonto for malignant hyperthermia

US WorldMeds is proud to announce the launch of Revonto™ (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH). The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear. Revonto™ retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

7 Jul 2010

MHAUS to discuss how medical facilities can best prepare for MH emergency

Preparation is the best plan for Malignant Hyperthermia emergencies, and The Malignant Hyperthermia Association of the United States will be at the Ambulatory Surgery Center Annual Meeting, May 19-22, to answer questions about how medical facilities can best prepare for an MH emergency.

20 May 2010

Data to advance the diagnosis, treatment and management of MH to be presented

Travel Award Available to share data with Clinicians and Scientists to advance the diagnosis, treatment, and management of Malignant Hyperthermia-Susceptible Patients April 23-24, 2010 at Mercy Hospital University of Pittsburgh Medical Center.

5 Mar 2010

MHAUS introduces new MH Mock Drill Training Kit to better prepare for MH emergencies

The Malignant Hyperthermia Association of the United States introduces a new MH Mock Drill Training Kit for Operating Room Staff to better prepare for MH emergencies

4 Mar 2010

Capsa Solutions acquires Artromick Mobile Solutions Group

Capsa Solutions, a leading provider of storage, processing and transport products, has announced the acquisition of Artromick Mobile Solutions Group and their comprehensive line of medication, medical and mobile computing carts for the extended and acute healthcare sectors. Artromick Mobile Solutions Group was previously owned by Sterling Partners, a Chicago and Baltimore-based private equity firm.

1 Dec 2009